Table 1

Baseline characteristics at index MI

Patients with STEMI
n=4657
Patients with NSTEMI
n=19 822
Total of patients with MI
n=24 479
Unknown (%)
Follow-up time (years), median (IQR)3.3 (1.4–5.7)3.9 (1.5–7.1)3.7 (1.5–6.7)0
Mean age, years (SD)65.7 (13.2)68.7 (13.2)68.1 (13.2)0
Male sex3311 (71.1%)12 658 (63.9%)15 969 (65.2%)0
Ethnicity4.8
 White3466 (76.4%)14 288 (76.1%)17 754 (76.2%)
 Asian83 (1.8%)327 (1.7%)410 (1.8%)
 Black20 (0.4%)63 (0.3%)83 (0.4%)
 Other968 (21.3%)4085 (21.7%)5053 (21.7%)
Body mass index (kg/m2)70.0
 Underweight (<18.5)22 (1.7%)120 (2.0%)142 (1.9%)
 Normal (18.5–25)335 (25.5%)1661 (27.4%)1996 (27.2%)
 Overweight (25–30)557 (43.0%)2431 (40.2%)2988 (40.7%)
 Obese (>30)381 (29.4%)1842 (30.4%)2223 (30.2%)
Index of Multiple Deprivation
Most deprived quintile
892 (19.2%)3985 (20.2%)4877 (20%)0.4
Risk factors before index MI
 Current smoker1235 (51.1%)3303 (39.5%)4538 (42.1%)55.9
 Excess alcohol consumption55 (9.0%)219 (8.1%)274 (8.3%)86.4
 History of atrial fibrillation358 (7.7%)2210 (11.1%)2568 (10.5%)0
 History of hypertension2117 (45.5%)10 141 (51.2%)12 258 (50.1%)0
 History of peripheral arterial disease236 (5.1%)1475 (7.4%)1711 (7%)0
Previous revascularisation
 PCI700 (15.0%)2044 (10.3%)2744 (11.2%)0
 CABG126 (2.7%)843 (4.3%)969 (4.0%)0
 Previous TIA154 (3.3%)998 (5.0%)1152 (4.7%)0
 Previous stroke80 (1.7%)410 (2.1%)490 (2.0%)0
 History of diabetes538 (11.6%)2476 (12.6%)3014 (12.3%)0
 History of thyroid disease237 (5.1%)1374 (6.9%)1661 (6.6%)0
 History of COPD304 (6.5%)1634 (8.2%)1938 (7.9%)0
 History of non-metastatic cancer478 (10.3%)2282 (11.5%)2760 (11.3%)0
Vital signs before admission, median (IQR)
 Systolic blood pressure, mm Hg140 (130–153)140 (130–154)140 (130–154)34.2
 Diastolic blood pressure, mm Hg80 (74–88)80 (71–88)80 (72–88)34.2
Biomarkers, median (IQR)
 Troponin I (maximum)18.4 (3.6–50.0)2.2 (0.3–10.0)3.88 (0.62–21.4)88.3
 Troponin T (maximum)1.8 (0.60–4.8)0.4 (0.14–1.1)0.65 (0.18–2)90.8
 CK (maximum)721 (222–1631)219 (97–648)331 (123–1068)79.8
Biomarkers before index MI, mean (SD)
 Haemoglobin, g/dL14.1 (1.72)13.6 (1.84)13.7 (1.83)67.1
 White cell count8.0 (2.94)7.9 (2.92)7.9 (2.92)69.1
 Neutrophil count5.0 (2.12)5.0 (2.40)5.0 (2.35)71.9
 Platelets270 (85.2)266 (88.0)267 (87.5)69.1
 Erythrocyte sedimentation rate19.5 (18.8)22.2 (21.6)21.8 (21.2)89.4
 Creatinine, µmol/L98.5 (39.1)102.5 (47.3)102 (46.0)58.7
 eGFR-CKD-EPI70.4 (19.9)66.2 (19.9)67.0 (20.0)60.4
 Random glucose concentration, mmol/L7.09 (3.53)7.26 (3.89)7.23 (3.82)76.5
 Total cholesterol5.39 (1.45)5.24 (1.28)5.27 (1.31)63.4
 LDL cholesterol3.24 (1.12)3.08 (1.10)3.11 (1.11)81.3
Revascularisation characteristics
 Site of infarction
 Anterior
393 (40.2%)255 (30.7%)648 (35.9%)92.6
 Primary PCI258 (19.3%)73 (3.2%)331 (9.2%)85.3
 Prehospital fibrinolysis324 (7.0%)94 (0.5%)418 (1.7%)0
 Median (IQR) delay from symptom to reperfusion (min)150 (98–280)160 (101–296)153 (99–285)88.3
Prescribed medication before index MI
 Antiplatelet867 (18.6%)6979 (35.2%)7846 (32.1%)0
 Oral anticoagulant67 (1.4%)624 (3.1%)691 (2.8%)0
 Statin825 (17.7%)5297 (26.7%)6122 (25.0%)0
 ACE inhibitor676 (14.5%)4363 (22.0%)5039 (20.6%)0
 Angiotensin receptor blocker220 (4.7%)1208 (6.1%)1428 (5.8%)0
 Beta-blocker766 (16.4%)5363 (27.1%)6129 (25.0%)0
 Calcium channel blocker804 (17.3%)4621 (23.3%)5425 (22.2%)0
 Loop diuretic255 (5.5%)2188 (11.0%)2443 (10.0%)0
 Aldosterone antagonist24 (0.5%)198 (1.0%)222 (0.9%)0
 Digoxin53 (1.1%)515 (2.6%)568 (2.3%)0
  • Prehospital and inhospital fibrinolysis are not mutually exclusive.

  • CABG, coronary artery bypass grafting; CK, creatine kinase; COPD, chronic obstructive pulmonary disease; eGFR-CKD-EPI, estimated glomerular filtration rate using CKD-EPI; LDL, low-density lipoprotein; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischaemic attack.